Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics

被引:5
|
作者
Jiang, Xia [1 ,2 ,3 ]
Li, Dabing [1 ,4 ]
Maghsoudloo, Mazaher [1 ]
Zhang, Xinghai [5 ]
Ma, Wenzhe [3 ]
Fu, Junjiang [1 ,2 ]
机构
[1] Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou, Peoples R China
[2] Southwest Med Univ, Dept Reprod Med, Affiliated Hosp, Luzhou, Sichuan, Peoples R China
[3] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China
[4] Southwest Med Univ, Sch Basic Med Sci, Luzhou, Sichuan, Peoples R China
[5] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, CAS Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China
基金
中国国家自然科学基金;
关键词
SARS-CoV-2; furin; COVID-19; furin inhibitors; therapeutics; CRYSTAL-STRUCTURES; POTENT INHIBITORS; SPIKE PROTEIN; CORONAVIRUS; CLEAVAGE; GLYCOPROTEIN; FUSION; VIRUS; ACTIVATION; SEQUENCE;
D O I
10.1016/j.drudis.2024.104026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
SARS-CoV-2 has triggered an international outbreak of the highly contagious acute respiratory disease known as COVID-19. Identifying key targets in the virus infection lifecycle is crucial for developing effective prevention and therapeutic strategies against it. Furin is a serine endoprotease that belongs to the family of proprotein convertases and plays a critical role in the entry of host cells by SARSCoV-2. Furin can cleave a speci fic S1/S2 site, PRRAR, on the spike protein of SARS-CoV-2, which promotes viral transmission by facilitating membrane fusion. Hence, targeting furin could hold clinical implications for the prevention and treatment of COVID-19. This review offers an overview of furin 's structure, substrates, function, and inhibitors, with a focus on its potential role in SARS-CoV-2 infection.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Therapeutics for COVID-19
    Toussi, Sima S.
    Hammond, Jennifer L.
    Gerstenberger, Brian S.
    Anderson, Annaliesa S.
    NATURE MICROBIOLOGY, 2023, 8 (05) : 771 - 786
  • [2] COVID-19 therapeutics
    Focosi, Daniele
    Franchini, Massimo
    Maggi, Fabrizio
    Shoham, Shmuel
    CLINICAL MICROBIOLOGY REVIEWS, 2024, 37 (02) : e0011923
  • [3] Therapeutics for COVID-19
    Sima S. Toussi
    Jennifer L. Hammond
    Brian S. Gerstenberger
    Annaliesa S. Anderson
    Nature Microbiology, 2023, 8 : 771 - 786
  • [4] The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19
    Schlom, Jeffrey
    Donahue, Renee N.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (09): : 1435 - 1438
  • [5] Advances in Targeting ACE2 for Developing COVID-19 Therapeutics
    Suvarnapathaki, Sanika
    Chauhan, Divya
    Nguyen, Angelina
    Ramalingam, Murugan
    Camci-Unal, Gulden
    ANNALS OF BIOMEDICAL ENGINEERING, 2022, 50 (12) : 1734 - 1749
  • [6] Advances in Targeting ACE2 for Developing COVID-19 Therapeutics
    Sanika Suvarnapathaki
    Divya Chauhan
    Angelina Nguyen
    Murugan Ramalingam
    Gulden Camci-Unal
    Annals of Biomedical Engineering, 2022, 50 : 1734 - 1749
  • [7] Furin: A Potential Therapeutic Target for COVID-19
    Wu, Canrong
    Zheng, Mengzhu
    Yang, Yueying
    Gu, Xiaoxia
    Yang, Kaiyin
    Li, Mingxue
    Liu, Yang
    Zhang, Qingzhe
    Zhang, Peng
    Wang, Yali
    Wang, Qiqi
    Xu, Yang
    Zhou, Yirong
    Zhang, Yonghui
    Chen, Lixia
    Li, Hua
    ISCIENCE, 2020, 23 (10)
  • [8] COVID-19: Vaccines and therapeutics
    Ponnampalli, Swapna
    Birudukota, Naga Venkata Suryanarayana
    Kamal, Ahmed
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 75
  • [9] COVID-19: Therapeutics and Their Toxicities
    Chary, Michael A.
    Barbuto, Alexander F.
    Izadmehr, Sudeh
    Hayes, Bryan D.
    Burns, Michele M.
    JOURNAL OF MEDICAL TOXICOLOGY, 2020, 16 (03) : 284 - 294
  • [10] COVID-19: Therapeutics and Their Toxicities
    Michael A. Chary
    Alexander F. Barbuto
    Sudeh Izadmehr
    Bryan D. Hayes
    Michele M. Burns
    Journal of Medical Toxicology, 2020, 16 : 284 - 294